PD-1 antibody (FITC)

Catalog No. ABIN2661634

Product Details anti-PD-1 Antibody (FITC)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PD-1 antibody is conjugated to FITC

Application: Flow Cytometry (FACS)

Cross-Reactivity: Chimpanzee, Marmoset, Rhesus Monkey, Squirrel Monkey (Saimiri spec.), Cynomolgus

Purification: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.

Clone: EH12-2H7

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: CD279 (PDCD1 Products)

Synonyms: CD279 antibody, PD-1 antibody, PD1 antibody, SLEB2 antibody, hPD-1 antibody, hPD-l antibody, Ly101 antibody, Pdc1 antibody, programmed cell death 1 antibody, PDCD1 antibody, Pdcd1 antibody

Background: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Pathways: Cancer Immune Checkpoints